These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 34952480)

  • 41. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.
    Dummer R; Lebbé C; Atkinson V; Mandalà M; Nathan PD; Arance A; Richtig E; Yamazaki N; Robert C; Schadendorf D; Tawbi HA; Ascierto PA; Ribas A; Flaherty KT; Pakhle N; Campbell CD; Gusenleitner D; Masood A; Brase JC; Gasal E; Long GV
    Nat Med; 2020 Oct; 26(10):1557-1563. PubMed ID: 33020648
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anticoagulation with Factor Xa Inhibitors Is Associated with Improved Overall Response and Progression-Free Survival in Patients with Metastatic Malignant Melanoma Receiving Immune Checkpoint Inhibitors-A Retrospective, Real-World Cohort Study.
    Haist M; Stege H; Pemler S; Heinz J; Fleischer MI; Graf C; Ruf W; Loquai C; Grabbe S
    Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680252
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PD-1 inhibitor monotherapy versus combination therapy: A real-world study of patients with recurrent or metastatic advanced esophageal squamous cell carcinoma after first-line chemotherapy.
    Yang G; Sun H; Zhou C; Sun N; Xu L; Huang W; Li B
    J Cancer Res Ther; 2022 Apr; 18(2):545-552. PubMed ID: 35645126
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immune checkpoint inhibitors and radiosurgery for newly diagnosed melanoma brain metastases.
    Robin TP; Breeze RE; Smith DE; Rusthoven CG; Lewis KD; Gonzalez R; Brill A; Saiki R; Stuhr K; Gaspar LE; Karam SD; Raben D; Kavanagh BD; Nath SK; Liu AK
    J Neurooncol; 2018 Oct; 140(1):55-62. PubMed ID: 29909499
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis.
    Versluis JM; Hendriks AM; Weppler AM; Brown LJ; de Joode K; Suijkerbuijk KPM; Zimmer L; Kapiteijn EW; Allayous C; Johnson DB; Hepner A; Mangana J; Bhave P; Jansen YJL; Trojaniello C; Atkinson V; Storey L; Lorigan P; Ascierto PA; Neyns B; Haydon A; Menzies AM; Long GV; Lebbe C; van der Veldt AAM; Carlino MS; Sandhu S; van Tinteren H; de Vries EGE; Blank CU; Jalving M
    Eur J Cancer; 2021 Jul; 151():72-83. PubMed ID: 33971447
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
    Liu J; Liu Q; Li Y; Li Q; Su F; Yao H; Su S; Wang Q; Jin L; Wang Y; Lau WY; Jiang Z; Song E
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448804
    [TBL] [Abstract][Full Text] [Related]  

  • 47. NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab ± everolimus for metastatic melanoma.
    McWilliams RR; Allred JB; Slostad JA; Katipamula R; Dronca RS; Rumilla KM; Erickson LA; Bryce AH; Joseph RW; Kottschade LA; King DM; Leitch JM; Markovic SN
    Cancer; 2018 Feb; 124(3):537-545. PubMed ID: 29044496
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Severe autoimmune hemolytic anemia following immunotherapy with checkpoint inhibitors in two patients with metastatic melanoma: a case report.
    Fetter T; Fietz S; Bertlich M; Braegelmann C; de Vos-Hillebrand L; Wenzel J; Heine A; Landsberg J; Jansen P
    Front Immunol; 2024; 15():1342845. PubMed ID: 38571955
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
    Buti S; Bersanelli M; Perrone F; Bracarda S; Di Maio M; Giusti R; Nigro O; Cortinovis DL; Aerts JGJV; Guaitoli G; Barbieri F; Ferrara MG; Bria E; Grossi F; Bareggi C; Berardi R; Torniai M; Cantini L; Sforza V; Genova C; Chiari R; Rocco D; Della Gravara L; Gori S; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; Citarella F; Russano M; Mazzoni F; Garassino MC; De Toma A; Signorelli D; Gelibter A; Siringo M; Follador A; Bisonni R; Tuzi A; Minuti G; Landi L; Ricciardi S; Migliorino MR; Tabbò F; Olmetto E; Metro G; Adamo V; Russo A; Spinelli GP; Banna GL; Addeo A; Friedlaender A; Cannita K; Porzio G; Ficorella C; Carmisciano L; Pinato DJ; Mazzaschi G; Tiseo M; Cortellini A
    Eur J Cancer; 2021 Jun; 150():224-231. PubMed ID: 33934059
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
    Fan Y; Huang ZY; Yu HF; Luo LH
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):859-63. PubMed ID: 21223694
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Is Immune Therapy Plus Chemotherapy More Effective Than Immune Therapy Alone for Unresectable Recurrent Nasopharyngeal Carcinoma?
    Zhou X; Niu X; Liu P; Ou D; Zhu Y; Wang X
    Front Immunol; 2021; 12():762663. PubMed ID: 34777379
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients.
    Basak EA; van der Meer JWM; Hurkmans DP; Schreurs MWJ; Oomen-de Hoop E; van der Veldt AAM; Bins S; Joosse A; Koolen SLW; Debets R; Peeters RP; Aerts JGJV; Mathijssen RHJ; Medici M
    Thyroid; 2020 Jul; 30(7):966-973. PubMed ID: 32151195
    [No Abstract]   [Full Text] [Related]  

  • 54. Impact of Immune Checkpoint Inhibitors with or without a Combination of Tyrosine Kinase Inhibitors on Organ-Specific Efficacy and Macrovascular Invasion in Advanced Hepatocellular Carcinoma.
    Kuo HY; Chiang NJ; Chuang CH; Chen CY; Wu IC; Chang TT; Tsai HM; Lin YJ
    Oncol Res Treat; 2020; 43(5):211-220. PubMed ID: 32101878
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or 
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
    Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Potential predictors for survival in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: A meta-analysis.
    Xu H; Cao D; Zheng Y; Zhou D; Chen X; Lei J; Ge W; Xu X
    Int Immunopharmacol; 2021 Nov; 100():108135. PubMed ID: 34530205
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
    Algazi AP; Tsai KK; Shoushtari AN; Munhoz RR; Eroglu Z; Piulats JM; Ott PA; Johnson DB; Hwang J; Daud AI; Sosman JA; Carvajal RD; Chmielowski B; Postow MA; Weber JS; Sullivan RJ
    Cancer; 2016 Nov; 122(21):3344-3353. PubMed ID: 27533448
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma.
    Fruehauf JP; El-Masry M; Osann K; Parmakhtiar B; Yamamoto M; Jakowatz JG
    Cancer Chemother Pharmacol; 2018 Aug; 82(2):353-360. PubMed ID: 29943192
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of CTLA-4 inhibitors combined with PD-1 inhibitors or chemotherapy in patients with advanced melanoma.
    Zhang B; Zhou YL; Chen X; Wang Z; Wang Q; Ju F; Ren S; Xu R; Xue Q; Wu Q
    Int Immunopharmacol; 2019 Mar; 68():131-136. PubMed ID: 30622030
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Decreased survival in patients treated by chemotherapy after targeted therapy compared to immunotherapy in metastatic melanoma.
    Mangin MA; Boespflug A; Maucort Boulch D; Vacheron CH; Carpentier I; Thomas L; Dalle S
    Cancer Med; 2021 May; 10(10):3155-3164. PubMed ID: 33932099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.